Low Cortisol Symptoms: Labs, Diagnosis, and Next Steps

Why Cortisol Drops Below Normal

Cortisol production depends on an intact hypothalamic-pituitary-adrenal (HPA) axis. Any disruption along this cascade reduces output. The clinical distinction that matters most: is the problem in the adrenal gland itself (primary) or in the pituitary/hypothalamus (secondary/tertiary)?

Primary adrenal insufficiency (Addison disease) results from destruction of the adrenal cortex. Autoimmune adrenalitis accounts for 80 to 90% of cases in industrialized countries [1]. The remaining cases stem from infections (tuberculosis remains the leading cause globally), bilateral adrenal hemorrhage, metastatic infiltration, or genetic disorders like adrenoleukodystrophy.

Secondary adrenal insufficiency is far more common. The Endocrine Society's 2016 clinical practice guideline estimates that chronic glucocorticoid therapy causes HPA axis suppression in patients taking prednisone equivalents of 5 mg or more daily for longer than 4 weeks [2]. Pituitary tumors, surgery, radiation, and infiltrative diseases round out the secondary causes. Abrupt withdrawal from exogenous steroids after prolonged use is the single most frequent trigger clinicians encounter in practice.

Tertiary insufficiency, sometimes grouped with secondary, involves hypothalamic dysfunction. Long-term opioid use suppresses CRH secretion and represents a growing contributor, with one study in the Journal of Clinical Endocrinology & Metabolism finding that 9 to 29% of patients on chronic opioids exhibit subnormal cortisol responses [3].

Recognizing the Symptom Pattern

The symptoms of low cortisol are nonspecific in isolation but form a recognizable constellation when grouped together. Fatigue is nearly universal, reported by over 95% of patients with confirmed adrenal insufficiency [4]. The fatigue worsens with exertion and does not resolve with sleep.

Other hallmark features include:

• Orthostatic hypotension (systolic drop of 20 mmHg or more on standing)
• Salt craving (specific to primary insufficiency due to concurrent aldosterone deficiency)
• Weight loss (typically 2 to 5 kg, sometimes more)
• Nausea, abdominal pain, and anorexia
• Hyperpigmentation of skin creases, gums, and scars (primary only, driven by elevated ACTH/MSH)
• Hyponatremia (present in up to 80% of adrenal crises)
• Hypoglycemia (more frequent in children and during fasting)

A key differentiator: hyperpigmentation and hyperkalemia point toward primary disease. Their absence in a patient with fatigue, hypotension, and hyponatremia suggests secondary or tertiary insufficiency. This distinction guides your provider toward the correct confirmatory testing pathway.

Which Labs to Order First

A single morning fasting serum cortisol (drawn between 7:00 and 9:00 AM, when cortisol peaks) is the appropriate screening test. The interpretation framework, per the Endocrine Society guideline [2]:

• Cortisol <3 µg/dL (83 nmol/L): highly suggestive of adrenal insufficiency; proceed to confirmatory testing or begin treatment if clinically urgent
• Cortisol 3 to 15 µg/dL: indeterminate; requires dynamic testing
• Cortisol >15 µg/dL (>414 nmol/L): adrenal insufficiency unlikely

Simultaneously draw a plasma ACTH level. If cortisol is low and ACTH is elevated (often >2x the upper limit of normal), primary adrenal insufficiency is the working diagnosis. If cortisol is low with ACTH that is low or inappropriately normal, suspect secondary/tertiary disease.

Additional labs to order with the initial panel:

• Basic metabolic panel (look for hyponatremia, hyperkalemia, hypoglycemia)
• DHEA-S (low in primary insufficiency; useful adjunct)
• Renin and aldosterone (elevated renin with low aldosterone supports primary disease)
• 21-hydroxylase antibodies (positive in autoimmune Addison disease in approximately 85% of cases) [5]

If your patient takes oral estrogen or has elevated sex hormone-binding globulin, total cortisol measurements can be falsely reassuring because estrogen raises cortisol-binding globulin. In that setting, a salivary cortisol or a free cortisol calculation provides more accurate assessment.

The ACTH Stimulation Test: Gold Standard

The 250 µg cosyntropin (synthetic ACTH) stimulation test remains the definitive diagnostic procedure. A baseline cortisol is drawn, 250 µg of cosyntropin is administered intravenously or intramuscularly, and cortisol is re-measured at 30 and 60 minutes [2].

A peak cortisol response below 18 µg/dL (500 nmol/L) at 30 or 60 minutes confirms adrenal insufficiency. Some newer immunoassays have shifted this cutoff; the 2016 Endocrine Society guideline notes that laboratories using newer platforms may find cutoffs of 14 to 15 µg/dL more appropriate [2]. Confirm your lab's assay-specific reference range.

The standard-dose test reliably detects primary insufficiency. For suspected recent-onset secondary insufficiency (within 4 to 6 weeks of a pituitary insult), the adrenal glands may not yet have atrophied and can still respond to exogenous ACTH. In this narrow window, the 1 µg low-dose cosyntropin test offers greater sensitivity, though it is technically more demanding and less standardized [6].

An insulin tolerance test (ITT) serves as the gold standard for assessing the entire HPA axis, including the hypothalamic-pituitary component. Peak cortisol below 18 µg/dL during symptomatic hypoglycemia (glucose <40 mg/dL) confirms central insufficiency [7]. The ITT is contraindicated in patients with seizure disorders or ischemic heart disease, limiting its practical use.

Imaging and Additional Workup

Once biochemistry confirms adrenal insufficiency, imaging clarifies the cause:

For primary disease: CT of the adrenal glands. Findings include bilateral adrenal atrophy (autoimmune), bilateral enlargement (infiltrative or infectious), calcifications (tuberculosis, hemorrhage), or masses (metastases). Autoimmune Addison disease typically shows small, non-calcified adrenals.

For secondary/tertiary disease: MRI of the pituitary with gadolinium contrast. Assess for adenomas, empty sella, or stalk lesions. A complete anterior pituitary hormone panel (TSH, free T4, LH, FSH, prolactin, IGF-1) should be obtained to evaluate for panhypopituitarism.

Tuberculosis testing is warranted in patients from endemic regions. Adrenoleukodystrophy screening (very long-chain fatty acids) should be considered in males with primary insufficiency of unclear etiology, especially those under age 50.

Treatment: Glucocorticoid Replacement

Physiologic replacement, not pharmacologic dosing, is the goal. The Endocrine Society recommends hydrocortisone 15 to 25 mg daily, divided into two or three doses [2]. A common regimen:

• 10 to 15 mg upon waking
• 5 to 10 mg at noon or early afternoon (no later than 4:00 PM to avoid sleep disruption)

Dr. Wiebke Arlt, whose research group at the University of Birmingham published extensively on adrenal replacement outcomes, has noted: "The challenge in adrenal insufficiency is replicating the circadian cortisol rhythm, something conventional immediate-release hydrocortisone does imperfectly" [8].

Modified-release hydrocortisone (Plenadren) delivers a more physiologic cortisol profile in a once-daily tablet. A randomized crossover trial (N=64) published in the Journal of Clinical Endocrinology & Metabolism demonstrated that Plenadren reduced body weight, HbA1c, and improved quality-of-life scores compared to conventional thrice-daily hydrocortisone over 12 weeks [9]. It remains more expensive and is not universally available.

Prednisolone (3 to 5 mg daily) or dexamethasone (0.25 to 0.5 mg daily) are alternatives, though their longer half-lives increase the risk of overreplacement, metabolic syndrome, and bone loss.

For primary insufficiency: add fludrocortisone 50 to 200 µg daily to replace aldosterone. Monitor supine and standing blood pressure, serum potassium, and plasma renin activity. Target renin in the upper normal range.

DHEA supplementation: The Endocrine Society suggests a trial of DHEA 25 to 50 mg daily in women with primary insufficiency who report impaired well-being or low libido despite optimized glucocorticoid and mineralocorticoid replacement [2]. Evidence quality is low, and response is variable.

Stress Dosing and Adrenal Crisis Prevention

Adrenal crisis is a medical emergency. A European retrospective study (N=423 patients with Addison disease, median follow-up 7.7 years) found an adrenal crisis incidence of 6.3 per 100 patient-years, with gastroenteritis and febrile infections as the most common precipitants [10]. Mortality per crisis episode ranges from 0.5 to 6% depending on recognition speed.

Every patient on chronic glucocorticoid replacement must receive written and verbal education on stress dosing:

• Minor febrile illness (temperature >38°C): double the oral hydrocortisone dose for the duration of illness
• Major illness, trauma, or inability to take oral medications: intramuscular hydrocortisone 100 mg stat, then 50 mg every 8 hours until stable
• Surgery under general anesthesia: hydrocortisone 100 mg IV at induction, then 50 mg every 8 hours for 24 to 72 hours depending on procedure magnitude

Patients should carry a medical alert identification and an emergency injection kit containing hydrocortisone 100 mg for intramuscular self-administration. The Endocrine Society explicitly recommends structured patient education programs, noting that patients who receive formal crisis prevention training experience 30 to 50% fewer crisis events [2].

Monitoring Long-Term Replacement

There is no single lab value that confirms optimal replacement dosing. Clinical assessment drives titration:

• Signs of underreplacement: persistent fatigue, nausea, weight loss, postural hypotension, hyponatremia
• Signs of overreplacement: weight gain (particularly central), hyperglycemia, insomnia, osteopenia, easy bruising

Serum cortisol day curves (measuring cortisol at multiple time points after dosing) can guide timing adjustments but are not routinely performed. A 24-hour urinary free cortisol that is persistently elevated suggests overreplacement.

Bone density monitoring via DXA every 2 to 3 years is appropriate, given that even physiologic-dose glucocorticoid replacement carries some bone loss risk over decades. The EU-AIR registry (European Adrenal Insufficiency Registry, N=2,594) identified osteoporosis in 10.4% of patients with adrenal insufficiency on replacement therapy [11].

Quality of life often remains impaired despite biochemically adequate replacement. The AddiQoL questionnaire, validated specifically for Addison disease, can track subjective well-being over time [12]. If fatigue persists despite appropriate dosing, evaluate for concurrent hypothyroidism (common in autoimmune polyglandular syndrome) and consider a DHEA trial.

When to Seek Urgent Care

Adrenal crisis manifests as severe hypotension (systolic <90 mmHg), altered consciousness, severe abdominal or back pain, and hypoglycemia. Any patient with known adrenal insufficiency who develops vomiting, diarrhea, or high fever and cannot retain oral medications must present for emergency parenteral hydrocortisone.

Do not wait for lab confirmation. The Endocrine Society guideline states: "In suspected adrenal crisis, we recommend immediate parenteral injection of 100 mg hydrocortisone followed by appropriate fluid resuscitation with isotonic saline, without waiting for results of diagnostic tests" [2].

Patients without a prior diagnosis can present in crisis as their first manifestation. A retrospective UK audit found that 50% of new Addison disease diagnoses occurred during or immediately after a crisis episode [13]. Emergency physicians should consider adrenal insufficiency in any patient with unexplained refractory hypotension, particularly if accompanied by hyponatremia and hyperkalemia.

Causes That Clinicians Miss

Several scenarios lead to delayed or missed diagnosis:

Chronic opioid use. As noted, opioid-induced adrenal insufficiency affects up to 29% of chronic users [3]. Fatigue in these patients is often attributed to the opioid itself rather than investigated endocrinologically.

Immune checkpoint inhibitors. Hypophysitis occurs in 5 to 17% of patients on ipilimumab and 1 to 5% on PD-1 inhibitors [14]. Secondary adrenal insufficiency from checkpoint inhibitor hypophysitis is often irreversible and requires lifelong replacement.

Post-traumatic brain injury. Pituitary dysfunction after TBI occurs in 15 to 68% of patients depending on severity and time from injury [15]. Screening at 3 and 12 months post-injury is recommended by the 2007 consensus statement published in the Journal of Clinical Endocrinology & Metabolism.

Glucocorticoid withdrawal after "short" courses. HPA suppression can occur after as few as 5 days of high-dose prednisone (40 to 60 mg daily). Rapid taper without assessing adrenal recovery leaves patients vulnerable.

Inhaled corticosteroids at high doses. Fluticasone propionate at doses exceeding 500 µg/day carries particular risk, especially in children.